Building successful life sciences companies.

With over $200 million of committed capital under management, Genesys is one of the largest Canadian-based exclusively focused on the life sciences industry. View our portfolio.

Building companies, accelerating development.

Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising life science investment opportunities.

Investor Login

Sign in to our secure investor area to receive personalized updates and information. Login now »

Recent Additions

Neurological disorder biotech Aptinyx files for a $80 million IPO
May 23, 2018 – Aptinyx, which is developing therapeutics for neurological disorders, filed on Wednesday with the SEC to raise up to $80 million in an initial public offering... Read more
Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration
EVANSTON, IL – May 22, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan... Read more